Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Is there a doctor in the Senate?

This article was originally published in The Tan Sheet

Executive Summary

A woman collapsed during the Oct. 21 Senate Health & Education Committee on FDAMA and awoke to find FDA Commissioner Jane Henney, MD, and Sen. Bill Frist, MD, tending to her health. Henney had been testifying when the woman collapsed and Frist (R-Tenn.) was chairing the hearing for an absent Sen. Jim Jeffords (R-Vt.). After transferring the patient to the Senate physician, Frist reassured hearing participants the woman was fine and had suffered only "a minor syncopal event." In other words, Henney clarified, "she fainted"

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts